AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28535817
Drug: Intravenous transplantation
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous transplantation of autologous bone marrow mesenchymal stromal cells (BMMSCs)
Trial: 28536126
Drug: Highest intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest intake of total sugars (median 137 g/d)
Trial: 28536126
Drug: Highest intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest intake of fructose (median 35.2 g/d)
Trial: 28536126
Drug: Highest intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Highest intake of sucrose (median 78 g/d)
Trial: 28536126
Drug: Lowest intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest intake of total sugars (median 65 g/d)
Trial: 28536126
Drug: Lowest intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest intake of fructose (median 9.7 g/d)
Trial: 28536126
Drug: Lowest intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest intake of sucrose (median 25.8 g/d)
Trial: 28537061
Drug: Dolutegravir 50
RxNorm normalized name: dolutegravir 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir 50 mg QD plus lamivudine 300 mg QD
Trial: 28538136
Drug: Evinacumab (human
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evinacumab (human monoclonal antibody)
Trial: 28538136
Drug: Control antibody
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control antibody
Trial: 28539464
Drug: Reparixin in
RxNorm normalized name: Reparixin
DrugBank: Reparixin (DB12614)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reparixin in combination with Weekly Paclitaxel
Trial: 28539464
Drug: Weekly Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly Paclitaxel
Trial: 28540640
Drug: Abemaciclib, doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib, doses ranging from 50 to 225 mg every 24 hours and 75 to 275 mg every 12 hours
Trial: 28542316
Drug: Non-reinstitution of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-reinstitution of aspirin until discharge
Trial: 28543053
Drug: Sofosbuvir 400
RxNorm normalized name: sofosbuvir 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir 400 mg once daily and weight-based ribavirin twice daily for 12 (genotype 2) or 24 (genotype 3) weeks
Trial: 28546135
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (ifosfamide and doxorubicin) with 5 days of hypofractionated radiotherapy (25 Gy in 5 fractions) during the second cycle of doxorubicin.
Trial: 28546135
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy (ifosfamide and doxorubicin) with hypofractionated RT.
Trial: 28546135
Drug: Hypofractionated RT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypofractionated RT combined with chemotherapy.
Trial: 28546463
Drug: Everolimus 10
RxNorm normalized name: everolimus 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus 10 mg/day plus Prednisone 5 mg b.i.d.
Trial: 28546581
Drug: Panobinostat (PAN)
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panobinostat (PAN) 30 mg plus Azacitidine (AZA) 75 mg/m²
Trial: 28546581
Drug: Azacitidine (AZA)
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine (AZA) monotherapy
Trial: 28549082
Drug: Propofol infusion
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol infusion in patients with frontal brain tumours
Trial: 28549424
Drug: Therapist-guided internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-guided internet-based cognitive behavior therapy (ePlus) for 12 weeks
Trial: 28549424
Drug: Therapist-guided internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-guided internet-based cognitive behavior therapy (ePlus)
Trial: 28551359
Drug: Pembrolizumab (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pembrolizumab (2 mg/kg or 10 mg/kg every 3 weeks, or 10 mg/kg every 2 weeks)
Trial: 28554602
Drug: Buprenorphine medication-assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine medication-assisted treatment (B-MAT)
Trial: 28555039
Drug: Polyunsaturated fatty
RxNorm normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyunsaturated fatty acids (PUFA) supplementation, dosage and duration not specified
Trial: 28558812
Drug: Onsite antenatal
RxNorm normalized name: DRESSING,OPSITE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Onsite antenatal syphilis screening intervention including onsite training, provision of supplies and medicines, quality control and supervision.
Trial: 28559537
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy followed by autologous stem cell transplantation (HCT-ASCT)
Trial: 28562108
Drug: Histamine-2-receptor antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine-2-receptor antagonists (H2RAs)
Trial: 28566263
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Treatment as usual with the endocrinologist and the nurse + Bodyguard2)
Trial: 28567369
Drug: Direct-acting antiviral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct-acting antiviral agents (DAAs) treatment
Trial: 28569047
Drug: Alglucerase/imiglucerase enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alglucerase/imiglucerase enzyme replacement therapy (ERT)
Trial: 28569206
Drug: 3-direct-acting-antiviral (DAA)
RxNorm normalized name: DIRECT BLUE 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-direct-acting-antiviral (DAA) regimen combining simeprevir (SMV), TMC647055/ritonavir (RTV), and JNJ-56914845
Trial: 28570742
Drug: Conformal radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conformal radiation therapy (RT) individualized to a fixed risk of RT-induced lung toxicity (RILT) and adaptively escalated to the residual tumor defined on midtreatment FDG-PET up to a total dose of 86 Gy in 30 daily fractions, with concurrent weekly carboplatin plus paclitaxel.
Trial: 28571635
Drug: β-blockers in
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-blockers in ST-segment elevation myocardial infarction
Trial: 28571635
Drug: β-blockers in
RxNorm normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: β-blockers in non-ST-segment elevation myocardial infarction
Trial: 28571635
Drug: No β-blockers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No β-blockers (Control)
Trial: 28574652
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg administered once daily
Trial: 28575278
Drug: 0.5 million
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 million IU (MIU) of nebulized colistin methanesulfonate (CMS) administered every 8 hours as 30-minute nebulizations
Trial: 28575299
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) treatment during childhood
Trial: 28575323
Drug: darunavir/ritonavir (800/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir/ritonavir (800/100 mg) once-daily regimen
Trial: 28575323
Drug: darunavir/cobicistat (800/150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir/cobicistat (800/150 mg) once-daily regimen
Trial: 28575523
Drug: Fidaxomicin (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fidaxomicin (16 mg/kg per day, up to 200 mg, twice daily for 10 days)
Trial: 28576754
Drug: Hydroxyurea treatment
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea treatment starting at approximately 20 mg/kg/day for 6 months, escalating to maximum tolerated dose (MTD) thereafter.
Trial: 28576754
Drug: Hydroxyurea at
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea at maximum tolerated dose (MTD).
Trial: 28577353
Drug: Simeprevir 150
RxNorm normalized name: simeprevir 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simeprevir 150 mg once daily plus Peginterferon α-2a/Ribavirin for 12 weeks followed by Peginterferon α-2a/Ribavirin for 12 or 36 weeks (response-guided therapy) or 36 weeks fixed (non-responders).
Trial: 28577957
Drug: Osimertinib (AZD9291)
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Osimertinib (AZD9291) treatment
Trial: 28578302
Drug: Antibiotics (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics (administered per standard of care for 5 days)
Trial: 28578302
Drug: Omeprazole (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (administered over 14 days)
Trial: 28578535
Drug: Increased daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased daily water intake over 6 weeks
Trial: 28579823
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) opioids (hydrocodone-acetaminophen and oxycodone-acetaminophen)
Trial: 28579823
Drug: Immediate-release (IR)
RxNorm normalized name: IR-3535
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate-release (IR) opioids
Trial: 28580793
Drug: Lanreotide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide plus Metformin (MET)
Trial: 28580917
Drug: Fragment antigen-binding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fragment antigen-binding domains (Fabs) isolated from human monoclonal antibodies targeting NHBA
Trial: 28581396
Drug: F-18 fluorodeoxyglucose
RxNorm normalized name: Fludeoxyglucose F-18
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: F-18 fluorodeoxyglucose (FDG) PET during chemoradiation therapy (CRT)
Trial: 28581691
Drug: Recombinant factor
RxNorm normalized name: Recombinant factor IX
DrugBank: Coagulation Factor IX (Recombinant) (DB00100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant factor XIII-A (rFXIII) prophylaxis, 35 IU/kg once monthly
Trial: 28582240
Drug: Tablet-based application
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based application (EPIC Wheels) with two in-person sessions and four weeks of independent home training
Trial: 28582240
Drug: Tablet-based application
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based application (EPIC Wheels) with expert trainer monitoring
Trial: 28582240
Drug: Tablet-based application
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based application (EPIC Wheels) with video instruction and interactive training games
Trial: 28582240
Drug: Tablet-based application
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet-based application (EPIC Wheels) with standardized configuration for Wi-Fi devices
Trial: 28583131
Drug: Store features
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Store features with health promoting characteristics (e.g., fruit/vegetable shelf space, Healthy Food Supply Score)
Trial: 28583305
Drug: DTaP5-IPV-HB-Hib vaccine
RxNorm normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP5-IPV-HB-Hib vaccine administered at 2 and 6 months of age, DTaP5-IPV-Hib at 4 months, MCC vaccine at 2 and 4 months, and routine rotavirus and pneumococcal vaccination.
Trial: 28583305
Drug: Mixed schedule
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed schedule including DTaP5-IPV-HB-Hib and MCC vaccine.
Trial: 28583305
Drug: Mixed schedule
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed schedule with hexavalent vaccine and MCC vaccine.
Trial: 28583305
Drug: Hexavalent vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexavalent vaccine co-administered with MCC vaccine.
Trial: 28583305
Drug: Study vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study vaccine doses.
Trial: 28583617
Drug: Implantable IV
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implantable IV infusion system for treprostinil
Trial: 28584140
Drug: CRS3123 (Methionyl-tRNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRS3123 (Methionyl-tRNA Synthetase Inhibitor)
Trial: 28584142
Drug: Micafungin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micafungin treatment
Trial: 28588421
Drug: Novel product
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel product containing glycolic acid, sodium bicarbonate, glycerin, and other buffering agents, applied once before irrigation with warm water
Trial: 28588426
Drug: Ramadan fasting
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramadan fasting (RF) with clopidogrel at a maintenance dose of 75 mg
Trial: 28588426
Drug: Clopidogrel at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel at a maintenance dose of 75 mg without Ramadan fasting
Trial: 28588982
Drug: RUTF-L
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RUTF-L
Trial: 28588992
Drug: mRDTs (malaria
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRDTs (malaria rapid diagnostic tests) introduced in drug shops
Trial: 28589492
Drug: LY2874455 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2874455 at 16 mg BID (RP2D)
Trial: 28592319
Drug: Daily 360
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 360 μg of menaquinone-7 for 4 weeks
Trial: 28592387
Drug: Dabrafenib plus
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dabrafenib plus trametinib (oral dabrafenib 150 mg twice per day and oral trametinib 2 mg once per day)
Trial: 28592434
Drug: Rosuvastatin treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin treatment for 2 years, starting at 5 mg once daily, uptitrated to 10 mg (age 6-<10 years) or 20 mg (age 10-<18 years).
Trial: 28592616
Drug: Panitumumab (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panitumumab (6 mg/kg, administered intravenously every 2 weeks)
Trial: 28592615
Drug: Cobimetinib and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cobimetinib and duligotuzumab combination
Trial: 28592624
Drug: Pemetrexed 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed 150 mg/m2 via 8-hour intravenous infusion followed by gemcitabine
Trial: 28593789
Drug: Angiotensin-converting enzyme
RxNorm normalized name: ACE - Angiotensin-converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers
Trial: 28594762
Drug: Shared decision-making
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shared decision-making intervention using a tablet computer-based decision aid for opioid prescribing after cesarean delivery.
Trial: 28594762
Drug: Standard prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard prescription of 40 tablets of 5 mg oxycodone.
Trial: 28595189
Drug: Oral BCAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral BCAA (30.7 ± 1.1 g)
Trial: 28595189
Drug: IV BCAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV BCAA (30.7 ± 1.1 g)
Trial: 28595339
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy (CRT-D) responders
Trial: 28595616
Drug: Oral ridaforolimus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ridaforolimus 30 mg daily for 5 consecutive days per week combined with intravenous paclitaxel 175 mg/m2
Trial: 28596794
Drug: Herbal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal therapy (5 shenwu capsules/administration, 3 times/day)
Trial: 28596794
Drug: Donepezil (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (placebo identical to donepezil tablets)
Trial: 28596794
Drug: Herbal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Herbal therapy
Trial: 28597842
Drug: Lacosamide (initiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacosamide (initiated at 100 mg/day, uptitrated to 200, 300, or 400 mg/day over 12 weeks)
Trial: 28598554
Drug: Biological brothers
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biological brothers
Trial: 28600132
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin 1·8 mg/kg once every 3 weeks for up to 16 cycles
Trial: 28600132
Drug: Physician's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's choice (oral methotrexate 5-50 mg once per week or oral bexarotene 300 mg/m2)
Trial: 28601434
Drug: Moroctocog alfa
RxNorm normalized name: MOROCTOCOG ALFA
DrugBank: Moroctocog alfa (DB13999)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Moroctocog alfa (AF-CC) 50 IU/kg IV
Trial: 28601641
Drug: Icatibant (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Icatibant (0.4 mg/kg; maximum 30 mg)
Trial: 28601826
Drug: Metformin and
RxNorm normalized name: metformin and acarbose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin and chloroquine
Trial: 28602587
Drug: Epidermal cell
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidermal cell suspension spray
Trial: 28602587
Drug: Noncultured keratinocyte
RxNorm normalized name: Foreskin keratinocyte (neonatal)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noncultured keratinocyte suspension
Trial: 28602585
Drug: Fedratinib 400
RxNorm normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fedratinib 400 mg once per day for six consecutive 28-day cycles
Trial: 28606999
Drug: Early dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early dual antiplatelet treatment
Trial: 28607547
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg + Domperidone 30 mg (group 1)
Trial: 28607547
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg (group 2)
Trial: 28607691
Drug: MIS416 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MIS416 administered once weekly for four weeks, then once weekly for up to 12 weeks at a dose of 500 µg/week.
Trial: 28607743
Drug: Subcutaneous peginterferon
RxNorm normalized name: peginterferon alfa-2a Injection [Pegasys]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous peginterferon beta-1a every 2 weeks
Trial: 28608617
Drug: Canagliflozin 100
RxNorm normalized name: canagliflozin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 100 mg added to teneligliptin 20 mg orally once daily for 52 weeks
Trial: 28610605
Drug: 12 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks of directly observed peg-interferon alfa-2b (PEG-IFN) and self-administered ribavirin
Trial: 28610605
Drug: 24 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 24 weeks of directly observed peg-interferon alfa-2b (PEG-IFN) and self-administered ribavirin
Trial: 28610605
Drug: 12 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12 weeks of therapy vs 24 weeks
Trial: 28611037
Drug: Empagliflozin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (25 mg/day) for 2 weeks
Trial: 28611126
Drug: Left Ventricular
RxNorm normalized name: DRESSING,VENTRICULAR ASSIST DEVICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left Ventricular Assist Device (LVAD) therapy
Trial: 28611778
Drug: Peg-Interferon Lambda
RxNorm normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peg-Interferon Lambda Treatment
Trial: 28612237
Drug: No L-thyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No L-thyroxine
Trial: 28613220
Drug: Intravitreal injections
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injections of Lucentis
Trial: 28614154
Drug: High-dose intralesional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intralesional ziv-aflibercept (0.1 mL to 0.3 mL, 2.5 mg to 7.5 mg)
Trial: 28614154
Drug: High-dose intralesional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intralesional ziv-aflibercept